Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 19 de 19
Filtrar
Más filtros

País/Región como asunto
Tipo del documento
Intervalo de año de publicación
1.
Transfus Apher Sci ; 60(1): 102913, 2021 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-32943324

RESUMEN

Anti-Hr0 (Anti-Rh17) is a rare immune Immunoglobulin G (IgG) to high-frequency Rh antigens that may cause severe and often fatal Hemolytic disease of the fetus and newborn (HDFN) in D--, Dc- and DCw- mothers who have been exposed to red cells of the common Rh phenotype by transfusion or pregnancy. Several pregnant women have been affected by this antibody leading to perinatal death. Therefore, immediate and effective management of these cases is of great importance. We report a case of HDFN in a 27-year-old (G5, P3, L1), woman with Rh Dc- phenotype managed successfully using intravenous immunoglobulin (IVIg) and simple transfusions.


Asunto(s)
Antígenos de Grupos Sanguíneos/efectos adversos , Eritroblastosis Fetal/genética , Sistema del Grupo Sanguíneo Rh-Hr/efectos adversos , Adulto , Femenino , Humanos , Fenotipo , Embarazo
2.
Haemophilia ; 23(4): 575-582, 2017 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-28440004

RESUMEN

INTRODUCTION: A room temperature stable formulation of recombinant activated factor VII (NovoSeven® ), allowing convenient storage and therefore improved treatment access, has been developed. Bioequivalence to the previous NovoSeven® was demonstrated in healthy humans, leading to European approval (2008). Although no confirmed cases of neutralising antibodies to rFVIIa in patients with haemophilia A or B have been observed with the original formulation, changes in formulation or storage condition may alter immunogenicity. AIM: SMART-7™ was designed to investigate the safety of NovoSeven® in a real-world setting in patients with haemophilia A or B with inhibitors. METHODS: Study medication was not provided by the sponsor, and treatment was at the discretion of the treating physician, in accordance with the local label. Patient baseline information was collected at enrolment. Information on safety, drug exposure and bleeding episodes was collected and FVII antibody screening was encouraged at baseline and performed at the investigator's discretion. RESULTS: Fifty-one patients were enrolled and 31 completed the study. Forty-one adverse events (AEs) were reported in 23 patients; 25 AEs in 14 patients were serious. No thromboembolic events were observed. Although four cases of reduced therapeutic response were reported, FVII antibody screening was negative. Forty-eight patients experienced 618 bleeding episodes and 93.4% of 609 evaluated bleeds were stopped by treatment. Of the 538 bleeding episodes treated with NovoSeven® monotherapy, 94.2% stopped by end of treatment. CONCLUSION: Data collected during the SMART-7™ study revealed no treatment-related safety issues and no FVII-binding antibodies for patients treated with NovoSeven® under real-world conditions.


Asunto(s)
Factor VIIa/efectos adversos , Factor VIIa/uso terapéutico , Hemofilia A/tratamiento farmacológico , Hemofilia B/tratamiento farmacológico , Seguridad , Temperatura , Adolescente , Adulto , Anciano , Niño , Preescolar , Estabilidad de Medicamentos , Factor VIIa/farmacología , Femenino , Hemofilia A/complicaciones , Hemofilia B/complicaciones , Hemorragia/complicaciones , Humanos , Lactante , Internacionalidad , Masculino , Persona de Mediana Edad , Proteínas Recombinantes/efectos adversos , Proteínas Recombinantes/farmacología , Proteínas Recombinantes/uso terapéutico , Resultado del Tratamiento , Adulto Joven
3.
Haemophilia ; 19(1): 65-70, 2013 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-22970656

RESUMEN

The purpose of this study was to investigate the dental and some other aspects of oral health status of young patients with congenital bleeding disorders (CBD) and the impact of these on their quality of life (OHR-QoL) compared with controls. DMFS-dmfs (Decayed, Missed, Filled Tooth surfaces in permanent and primary teeth) scores, Simplified oral hygiene index, occurance of hypoplasia of first permanent molars, Temporomandibular joint dysfunction and occlusion of 46 CBD patients at the age range of 2-15 years and 46 of other children as control were compared, and the impact of their oral health situation on quality of life was also investigated. Data were analysed by chi-square, t-test and Pearson correlation. Patients were significantly more caries-free with less decayed teeth in primary-permanent dentition (P = 0.03, t = -2.17).The mean scores of OHR-QoL of CBD patients and controls were not significantly different. Oral Bleeding was the significant variable in relation to 'oral health-related quality of life' in CBD groups (Pearson correlation, r = -0.56, P = 0.000). OHR-QoL in the control group was related to dmfs score (r = -0.392, P = 0.011) and male gender (r = -0.329, P = 0.026). Congenital bleeding disorder CBD patients were found to have a better dental health situation in primary dentition compared with controls; however, their 'oral health-related quality of life' was similar. Oral bleeding was the only significant factor related to OHR-QoL in CBD. It shows an overall importance of development of comprehensive care centres for CBD as the main cause of this achievement.


Asunto(s)
Trastornos de la Coagulación Sanguínea Heredados/complicaciones , Encuestas de Salud Bucal , Salud Bucal , Calidad de Vida , Adolescente , Trastornos de la Coagulación Sanguínea Heredados/psicología , Niño , Preescolar , Femenino , Hemorragia/etiología , Humanos , Masculino , Enfermedades de la Boca/etiología , Encuestas y Cuestionarios , Enfermedades Dentales/etiología
4.
Haemophilia ; 19(5): 668-73, 2013 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-23590670

RESUMEN

Over recent decades tremendous progress has been made in diagnosing and treating haemophilia and, in resource-rich countries, life expectancy of people with haemophilia (PWH) is now close to that of a healthy person. However, an estimated 70% of PWH are not diagnosed or are undertreated; the majority of whom live in countries with developing health care systems. In these countries, designated registries for people with haemophilia are often limited and comprehensive information on the natural history of the disease and treatment outcomes is lacking. Taken together, this means that planning efforts for future treatment and care of affected individuals is constrained in countries where it is most needed. Establishment of standardized national registries in these countries would be a step towards obtaining reliable sociodemographic and clinical data for an entire country. A series of consensus meetings with experts from widely differing countries with different health care systems took place to discuss concerns specific to countries with developing health care systems. As a result of these discussions, recommendations are made on parameters to include when establishing and harmonizing national registries. Such recommendations should enable countries with developing health care systems to establish standardized national haemophilia registries. Although not a primary objective, the recommendations should also help standardized data collation on an international level, enabling treatment and health care trends to be monitored across groups of countries and providing data for advocacy purposes. Greater standardization of data collation should have implications for optimizing resources for haemophilia care both nationally and internationally.


Asunto(s)
Atención a la Salud/organización & administración , Hemofilia A/diagnóstico , Hemofilia A/terapia , Sistema de Registros , Países en Desarrollo , Femenino , Hemofilia A/epidemiología , Humanos , Masculino
5.
Haemophilia ; 18(5): 773-6, 2012 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-22458944

RESUMEN

To prevent pregnancy loss in women with severe FXIII deficiency, prophylactic replacement therapy with a source of FXIII throughout pregnancy is essential. The aim of this study was to evaluate the bleeding score and rate of successful deliveries in FXIII-deficient pregnant Iranian women receiving regular prophylaxis. Seventeen FXIII-deficient women 18-35 years old (mean 24 years) were enrolled in the study. All patients except one had a history of at least one miscarriage. Patients received regular prophylaxis with 10 IU kg(-1) FXIII concentrate every 4 weeks before pregnancy and every 2 weeks during pregnancy for a period of 24-62 months. All bleeding episodes were recorded, and the bleeding score was determined on a standard form before and after the start of prophylaxis. After starting prophylaxis, monochloroacetic acid tests and 5 m urea tests were normal in all patients, and the bleeding score significantly decreased from 11-16 (mean 12 ± 1.5) to 23 (mean 2.2 ± 0.4) (P < 0.001). Thirteen minor bleeding episodes occurred during prophylaxis. All patients successfully delivered at 36 weeks' gestation and there were no significant coagulation complications during or after delivery. In this study, successful pregnancy maintenance and delivery were achieved in Iranian women with severe FXIII deficiency. Precise detection and diagnosis of this condition in women with coagulation disorders is essential to enable implementation of appropriate prophylaxis to prevent pregnancy loss.


Asunto(s)
Deficiencia del Factor XIII/complicaciones , Complicaciones Hematológicas del Embarazo , Aborto Espontáneo/prevención & control , Adolescente , Adulto , Estudios Transversales , Parto Obstétrico , Factor XIII/administración & dosificación , Deficiencia del Factor XIII/terapia , Femenino , Hemorragia/prevención & control , Hemorragia/terapia , Humanos , Irán , Masculino , Embarazo , Complicaciones Hematológicas del Embarazo/prevención & control , Complicaciones Hematológicas del Embarazo/terapia , Resultado del Embarazo , Estudios Prospectivos
6.
Haemophilia ; 18(2): 211-5, 2012 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-21854511

RESUMEN

We aimed to evaluate the effect of regular prophylaxis with a Factor X (FX) concentrate for patients with severe FXD in Iran and to assess the correlation of the genotype and phenotype in these patients. Ten patients with severe FXD (FX activity <1%) were enrolled and characterized during 2010-2011. Prophylaxis with 20 IU FX P Behring per kg body weight was administered once a week. FX levels, were monitored at baseline, 15 and 30 min, 1, 3, 6, 12, 24, 48, 72 and 96 h after starting prophylaxis. All patients were followed for 1 year. The mean age of the patients was 15 ± 7.8 years (age range of: 6-27 years). One patient had anaphylactic reaction after the first infusion, and the treatment was stopped. During one-year follow-up after starting prophylaxis, no bleeding symptoms occurred in any patient who tolerated and remained on the prophylaxis programme and all of them had a FX level of 1% or above. The maximum level of FX activity has been observed at 15 min after starting prophylaxis. A level of 1.5-3.5% was detected after 96 h. Homozygous mutations p.Arg40Thr (Arg-1Thr), p.Gly51Arg and p.Glu69Lys were detected in patients with intracranial haemorrhage. In our patients, significant decrease in symptoms without any complication after administration of FX, was demonstrated in all except one patient who had an anaphylactic reaction. It seems that the dose of 20 IU kg(-1) could be probably the best choice for patients with severe FXD, who require regular prophylaxis.


Asunto(s)
Deficiencia del Factor X/tratamiento farmacológico , Deficiencia del Factor X/genética , Factor X/administración & dosificación , Factor X/genética , Adolescente , Adulto , Niño , Factor X/efectos adversos , Factor X/análisis , Femenino , Estudios de Asociación Genética , Humanos , Irán , Masculino , Adulto Joven
7.
Prenat Diagn ; 31(8): 788-91, 2011 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-21692087

RESUMEN

OBJECTIVE: To determine the molecular spectrum of ß-thalassemia mutations among at-risk Balouch couples in Iran. METHODS: Mutations' detection in DNAs extracted from the blood of partners of at-risk couples was characterized, and chorion villus sampling by amplification refractory mutation system and DNA sequencing was performed. Fetal diagnosis was also confirmed by linkage analysis. RESULTS: Out of a total of 1234 at-risk Balouch couples referred to the center for prenatal diagnosis (PND) from June 2002 to June 2010, a high percentage of '67.4%' were from consanguineous marriages and 37.4% had between one and four affected children. The trend in referring gradually increased from 34 cases in 2002 to 357 cases in 2010. The astonishing finding was that, unlike most previous studies, only IVS 1-5 with an unusual frequency of 87.20% along with codon 8/9 (+G) with 4% constitutes about 91% of mutations. Altogether, 729 PNDs were made in 583 couples, 25% of whom had over one PND, and surprisingly five PNDs were made in the same woman within just 8 years. CONCLUSION: Regarding the limited types of frequent mutations among Balouch population, it is hopefully believed that the incidence of ß-thalassemia could be controlled by a correct diagnosis in the due time.


Asunto(s)
Talasemia beta/genética , Adolescente , Adulto , Consanguinidad , Análisis Mutacional de ADN , Femenino , Humanos , Irán , Masculino , Persona de Mediana Edad , Mutación , Diagnóstico Prenatal , Adulto Joven , Talasemia beta/diagnóstico
8.
East Mediterr Health J ; 17(6): 552-6, 2011 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-21796975

RESUMEN

The unintentional contamination of haemophilia patients with HIV in the early 1980s raised serious questions about the safety of blood product supplies worldwide. The events initiated a cascade of consequences for both infected patients and the national health systems of many countries, including the Islamic Republic of Iran. Lawsuits have been filed in the courts mostly in developed countries, leading to the establishment of some kind of reimbursement programme for haemophilia patients who acquired viral infections. In the late 1990s the courts ordered the Iranian Ministry of Health, in addition to providing free care with the latest treatments to pay compensation to the haemophilia patients. The adverse consequences of these events on the equitable distribution of resources in the Iranian health care system are discussed in this paper.


Asunto(s)
Programas de Gobierno , Infecciones por VIH/economía , Hemofilia A/complicaciones , Hepatitis C/economía , Reacción a la Transfusión , Transfusión Sanguínea/historia , Infecciones por VIH/etiología , Hemofilia A/historia , Hemofilia A/terapia , Hepatitis C/etiología , Historia del Siglo XX , Humanos , Irán/epidemiología
11.
Clin Appl Thromb Hemost ; 22(2): 184-90, 2016 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-25343955

RESUMEN

INTRODUCTION: This study compared the efficacy of Aryoseven with Novoseven to control bleeding episodes in patients with hemophilia A with inhibitors. METHODS: Sixty-six patients were randomized into 2 groups, with 4 consecutive block randomization. These groups received Aryoseven and Novoseven dosages of 90 to 120 µg/kg intravenously every 2 hours. RESULTS: Median (interquartile range) level of factor VIII (FVIII) inhibitor in groups A and B was 15.0 and 19.0 Bethesda Unit (BU) preadministration. Bleeding onset in group A was 1246 ± 1104 minutes and in group B was 2301 ± 1693 minutes (P = .311). The Kavakli global response scores and treatment success rate was comparable in both the groups. The side effects in groups A (9.7%) and B (2.9%) were comparable. CONCLUSION: Biosimilar recombinant activated FVII is found to be as effective as Novoseven in the treatment of acute joint bleeding in patients with hemophilia with inhibitors. Its usage will decrease the gaps in hemophilia.


Asunto(s)
Biosimilares Farmacéuticos/administración & dosificación , Inhibidores de Factor de Coagulación Sanguínea/sangre , Factor VIIa/administración & dosificación , Hemofilia A/tratamiento farmacológico , Hemorragia/tratamiento farmacológico , Adolescente , Adulto , Niño , Femenino , Hemofilia A/sangre , Hemorragia/sangre , Humanos , Masculino , Proteínas Recombinantes/administración & dosificación , Factores de Tiempo
13.
Clin Appl Thromb Hemost ; 21(8): 724-8, 2015 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-24651301

RESUMEN

In order to establish the efficacy and biosimilar nature of AryoSeven to NovoSeven in the treatment of congenital factor VII (FVII) deficiency, patients received either agent at 30 µg/kg, intravenously per week for 4 weeks, in a randomized fashion. The primary aim was to compare FVII:coagulation activity (FVII:C), 20 minutes after recombinant activated FVII (rFVIIa) injection, in the 2 groups. A secondary measure was self-reported bleeding. The median interquartile baseline range of the plasma level of activated FVII (FVIIa) activity in the 2 groups was 1.6 (1.1-14.0) IU/dL and 5.0 (1.1-25.5) IU/dL. All patients achieved levels of FVIIa (FVII:C) >30 IU/dL, 20 minutes after the injection of rFVIIa. Bleeding was similar between the 2 groups, with a comparable decrease in severity and frequency compared to the last month prior to treatment. AryoSeven is similar to NovoSeven in increasing postinjection FVIIa activity as well as in clinical safety and efficacy.


Asunto(s)
Deficiencia del Factor VII/tratamiento farmacológico , Factor VIIa/administración & dosificación , Factor VIIa/farmacocinética , Adolescente , Adulto , Coagulación Sanguínea/efectos de los fármacos , Niño , Método Doble Ciego , Deficiencia del Factor VII/sangre , Factor VIIa/efectos adversos , Femenino , Hemorragia/sangre , Hemorragia/inducido químicamente , Humanos , Masculino , Proteínas Recombinantes/administración & dosificación , Proteínas Recombinantes/efectos adversos , Proteínas Recombinantes/farmacocinética
14.
Hematology ; 19(6): 361-4, 2014 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-24164872

RESUMEN

OBJECTIVE: The aim of this study was to assess the effectiveness of localized treatments to persistently stop epistaxis in patients with inherited bleeding disorders. METHODS: In a self-controlled comparative clinical trial, to offer the best solution to stop epistaxis at home (within 10 minutes), patients with inherited bleeding disorders were treated using three different topical hemostatic agents, including Tranexamic acid impregnated tampon, EpiCell tampon prepared from oxidized regenerated cellulose pad, and ChitoHem tampon (reinforced with chitosan). The results of using these different products on three groups of randomly selected patients were ultimately compared using the χ(2) and Fisher's exact test statistics. RESULTS: A total of 31 patients, 5 females and 26 males with a mean age of 5.6 years, were included in the study. Twenty-three patients had Glanzmann disease, four had von-Willebrand disease, two had Bernard soulier syndrome, two had activated factor VII deficiency, and one patient had impaired secretion of adenosine deaminase. The study exhibited that statistically there was no significant difference between EpiCell tampon and Tranexamic acid impregnated tampon treatments with respect to the hemostasis duration. However, ChitoHem tampon was more efficient than Tranexamic acid impregnated tampon (P value <0.001) and EpiCell tampon (P value < 0.05). CONCLUSION: ChitoHem tampon, the chitosan-reinforced product, was the best therapy solution to stop epistaxis. We recommend further research on the use of other hemostatic agents for localized bleeding in patients with inherited bleeding disorders.


Asunto(s)
Trastornos de la Coagulación Sanguínea Heredados/complicaciones , Celulosa/uso terapéutico , Quitosano/uso terapéutico , Epistaxis/complicaciones , Epistaxis/tratamiento farmacológico , Hemostáticos/uso terapéutico , Ácido Tranexámico/uso terapéutico , Administración Tópica , Trastornos de la Coagulación Sanguínea Heredados/sangre , Trastornos de la Coagulación Sanguínea Heredados/tratamiento farmacológico , Celulosa/administración & dosificación , Niño , Preescolar , Quitosano/administración & dosificación , Epistaxis/sangre , Femenino , Hemostasis/efectos de los fármacos , Hemostáticos/administración & dosificación , Humanos , Masculino , Ácido Tranexámico/administración & dosificación
15.
Iran J Ped Hematol Oncol ; 3(4): 164-72, 2013.
Artículo en Inglés | MEDLINE | ID: mdl-24575291

RESUMEN

Factor XIII or "fibrin-stabilizing factor," is a transglutaminase circulates in the blood circulation as a hetero tetramer with two catalytic A subunits and two carrier B subunits. This important coagulation factor has a crucial role in clotting cascade and produces strong covalent bonds between soluble formed fibrin monomers during coagulation. This stable cross linked fibrin strands are resistanttodegradationby thefibrinolyticsystem that enablesthe bodyto stoppotential bleeding episodes. In the absence or severe decrease of factor XIII, although the clot is formed, but is rapidly degraded by the fibrinolytic system, and delayed bleedingoccurs.Factor XIII deficiency is an extremely rare bleeding disorder with estimated incidence of 1/2-3000, 000 in the general population. Presumptive diagnosis of factor XIII deficiency was by clot solubility test in 5M urea or 1% monochloroacetic acid environments. In patients with abnormal screening clot solubility test, the disease can be confirmedbymore specifictestssuch as quantitative factor XIII activity assay andFXIIIAgassay.After diagnosis of disease all patients with severe factor XIII deficiency(<1 U/dl) shouldreceive prophylactic substitution therapywith fresh frozen plasma (FFP) and cryoprecipitate as traditional choices or purified concentrateof blood coagulation factor XIII (Fibrogammin P) inorder to control severe and life-threatening clinical complications of factor XIII deficiency.

16.
Daru ; 19(3): 240-8, 2011.
Artículo en Inglés | MEDLINE | ID: mdl-22615664

RESUMEN

PURPOSE OF THE STUDY: to determine the efficacy, adverse effects and safety of a new Iranian generic product of deferasirox (Osveral®) in Iranian transfusion dependent major thalassemic (TD-MT) patients. METHODS: In 9 main thalassemia treatment centers, all of TD-MT patients (aged ≥2 yrs) with serum ferritin (SF) levels≥1000 ng/ml, or >100 ml/kg of RBC transfusion,who could not tolerate parental iron chelating were recruited regardless of their previous iron chelation therapy. Periodical clinical and laboratory evaluations were conducted for adverse effects (AEs). Primary efficacy end point was Mean of Relative Change of Serum Ferritin (MRC-SF) from the baseline level during one year. Analysis of variance (ANOVA), t test, chi-square or Fisher exact test were used for statistic analysis appropriately (P values <0.05 were considered as statistical significant). RESULTS: In 407 cases the male/female ratio was 0.98. Mean age was 11.5±7.4 (2-58) years. The mean of initiating dose of Osveral® and mean usage dose during the study was 23.5±4.9 mg/kg and 24.9±4.9 mg/kg respectively. MRC-SF was -11.44% ±38.92 and it showed significant decline in SF (P value<0.001) one hundred and forty eight patients out of 407 patients experienced at least one. AE, the most common of them were transient increase in serum creatinin (97;24.1%) and>5 time increase in transaminases (24;5.89%).The causes of discontinuation of treatment were non-satisfactory treatment ( 24; 5.8%), poor or non-compliance of patients (21;5.1%), and adverse effects (13; 3.1%) CONCLUSION: A detailed comparison with similar studies on deferasirox (Exjade®) shows a promising efficacy and safety for its Iranian generic product (Osveral ®).

17.
Indian J Pediatr ; 73(7): 619-22, 2006 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-16877858

RESUMEN

Lymphoblastic lymphoma-leukemia (LBLL) most commonly presents with mediastinal masses (50-75%), while pleural and pericardial effusion may also be present. Lymphadenopathy usually in the neck, axilla or supraclavicular regions, is considered as another typical presentation of the disease. This is a case report of a six-year-old boy with unusual huge enlargement of maxilla, mandible and soft palate as well as gingival hypertrophy which led to secondary respiratory and feeding difficulties. Morphologic and flowcytometric evaluation of bone marrow aspiration showed that it was a T cell type acute leukemia which may be due to dissemination of a lymphoblastic lymphoma and considered as a case of lymphoma-leukemia. After appropriate treatment, the symptoms of the patient relieved significantly and he is in complete remission for about one year.


Asunto(s)
Hipertrofia Gingival/etiología , Enfermedades Maxilomandibulares/etiología , Leucemia-Linfoma Linfoblástico de Células Precursoras/diagnóstico , Niño , Humanos , Irán , Leucemia Linfoide/complicaciones , Leucemia Linfoide/diagnóstico , Masculino , Leucemia-Linfoma Linfoblástico de Células Precursoras/complicaciones
19.
(East. Mediterr. health j).
en Inglés | WHOLIS | ID: who-118657

RESUMEN

The unintentional contamination of haemophilia patients with HIV in the early 1980s raised serious questions about the safety of blood product supplies worldwide. The events initiated a cascade of consequences for both infected patients and the national health systems of many countries, including the Islamic Republic of Iran. Lawsuits have been filed in the courts mostly in developed countries, leading to the establishment of some kind of reimbursement programme for haemophilia patients who acquired viral infections. In the late 1990s the courts ordered the Iranian Ministry of Health, in addition to providing free care with the latest treatments, to pay compensation to the haemophilia patients. The adverse consequences of these events on the equitable distribution of resources in the Iranian health care system are discussed in this paper


Asunto(s)
Hemofilia A , Infecciones por VIH , Hepatitis B , Hepatitis C , Patógenos Transmitidos por la Sangre
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA